AstraZeneca's Pill Can Cut Lung Cancer Deaths in Half

AstraZeneca's Pill Can Cut Lung Cancer Deaths in Half

A groundbreaking clinical trial has demonstrated that a daily pill developed by AstraZeneca significantly reduces deaths among early-stage lung cancer patients who have undergone surgery. The results, presented at the American Society of Clinical Oncology's annual meeting and published in the New England Journal of Medicine, revealed that patients who took the Pill, known as Tagrisso, for three years experienced a 51% lower risk of death from the disease.

Involving 682 lung cancer patients from over 20 countries, the trial revealed that the Pill decreased the chance of death from lung cancer by 51% overall. Dr. Roy Herbst, the trial's principal investigator and deputy director at Yale Cancer Center, hailed the findings as a major step forward in lung cancer treatment, stating, "I think we're curing some patients. We are making significant advancements in lung cancer treatment, more than ever before."

The study focused on patients with early-stage lung cancer who had a mutation in an EGFR receptor, which contributes to cancer cell growth. This mutation is often found in Asia and Australia and is typically detected in individuals with little to no smoking history. Tagrisso acts as an "off" switch for the mutated receptor, preventing excessive cell division and multiplication.

The success of targeted treatments like Tagrisso has revolutionized lung cancer treatment, improving survival rates significantly, and may eventually be combined with chemotherapy for optimal results. The survival data from this trial is expected to lead to increased prescriptions of Tagrisso and wider insurance coverage for the drug. The researchers also emphasized that Tagrisso offers fewer major side effects than chemotherapy, making it a more tolerable treatment option for patients.

The researchers hope the compelling data will serve as a call to action for increased screenings and testing for EGFR mutations, leading to earlier detection and improved outcomes for lung cancer patients.

IJCP Editorial Team

Comprising seasoned professionals and experts from the medical field, the IJCP editorial team is dedicated to delivering timely and accurate content and thriving to provide attention-grabbing information for the readers. What sets them apart are their diverse expertise, spanning academia, research, and clinical practice, and their dedication to upholding the highest standards of quality and integrity. With a wealth of experience and a commitment to excellence, the IJCP editorial team strives to provide valuable perspectives, the latest trends, and in-depth analyses across various medical domains, all in a way that keeps you interested and engaged.

 More FAQs by IJCP Editorial Team


Medtalks is India's fastest growing Healthcare Learning and Patient Education Platform designed and developed to help doctors and other medical professionals to cater educational and training needs and to discover, discuss and learn the latest and best practices across 100+ medical specialties. Also find India Healthcare Latest Health News & Updates on the India Healthcare at Medtalks